BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38112272)

  • 1. Extracting forced vital capacity from the electronic health record through natural language processing in rheumatoid arthritis-associated interstitial lung disease.
    England BR; Roul P; Yang Y; Hershberger D; Sayles H; Rojas J; Cannon GW; Sauer BC; Curtis JR; Baker JF; Mikuls TR
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5744. PubMed ID: 38112272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
    Chartrand S; Lee JS; Swigris JJ; Stanchev L; Fischer A
    Lung; 2019 Dec; 197(6):709-713. PubMed ID: 31583453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning.
    Román Ivorra JA; Trallero-Araguas E; Lopez Lasanta M; Cebrián L; Lojo L; López-Muñíz B; Fernández-Melon J; Núñez B; Silva-Fernández L; Veiga Cabello R; Ahijado P; De la Morena Barrio I; Costas Torrijo N; Safont B; Ornilla E; Restrepo J; Campo A; Andreu JL; Díez E; López Robles A; Bollo E; Benavent D; Vilanova D; Luján Valdés S; Castellanos-Moreira R
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
    Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
    Xie M; Zhu C; Ye Y
    BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
    Morisset J; Vittinghoff E; Lee BY; Tonelli R; Hu X; Elicker BM; Ryu JH; Jones KD; Cerri S; Manfredi A; Sebastiani M; Gross AJ; Ley B; Wolters PJ; King TE; Kim DS; Collard HR; Lee JS
    Respir Med; 2017 Jun; 127():51-56. PubMed ID: 28502419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease.
    Chen J; Shi Y; Wang X; Huang H; Ascherman D
    Clin Dev Immunol; 2013; 2013():406927. PubMed ID: 23983768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Zamora-Legoff JA; Krause ML; Crowson CS; Ryu JH; Matteson EL
    Arthritis Rheumatol; 2017 Mar; 69(3):542-549. PubMed ID: 27788297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.
    Hozumi H; Kono M; Hasegawa H; Kato S; Inoue Y; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura Y; Yokomura K; Nakamura H; Suda T
    Respir Res; 2022 Mar; 23(1):57. PubMed ID: 35277175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis.
    Xu L; Jiang L; Nie L; Zhang S; Liu L; Du Y; Xue J
    BMC Immunol; 2021 Oct; 22(1):69. PubMed ID: 34654367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?
    Nurmi HM; Purokivi MK; Kärkkäinen MS; Kettunen HP; Selander TA; Kaarteenaho RL
    BMC Pulm Med; 2017 Jan; 17(1):16. PubMed ID: 28086844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.
    Kelly CA; Saravanan V; Nisar M; Arthanari S; Woodhead FA; Price-Forbes AN; Dawson J; Sathi N; Ahmad Y; Koduri G; Young A;
    Rheumatology (Oxford); 2014 Sep; 53(9):1676-82. PubMed ID: 24758887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis.
    Cho SK; Doyle TJ; Lee H; Jin Y; Tong AY; Ortiz AJS; Sparks JA; Kim SC
    Semin Arthritis Rheum; 2020 Aug; 50(4):592-597. PubMed ID: 32480097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease.
    Chang SH; Lee JS; Ha YJ; Kim MU; Park CH; Lee JS; Kim JW; Chung SW; Pyo JY; Lee SW; Kang EH; Lee YA; Park YB; Choe JY; Lee EY
    Rheumatology (Oxford); 2023 Sep; 62(9):3014-3024. PubMed ID: 36702465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease.
    Brooks R; Baker JF; Yang Y; Roul P; Kerr GS; Reimold AM; Kunkel G; Wysham KD; Singh N; Lazaro D; Monach PA; Poole JA; Ascherman DP; Mikuls TR; England BR
    Rheumatology (Oxford); 2022 Nov; 61(12):4667-4677. PubMed ID: 35377443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease.
    Zheng B; Donohoe K; Hambly N; Johannson KA; Assayag D; Fisher JH; Manganas H; Marcoux V; Khalil N; Kolb M; Ryerson CJ;
    Respirology; 2022 Oct; 27(10):854-862. PubMed ID: 35652240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.